The term peritoneal sclerosis can be applied to a vast range of peritoneal alterations. At one end of the range we have the slight peritoneal sclerosis constantly associated with peritoneal dialysis, which may be defined as simple sclerosis. Its clinical impact is slight. The role of glucose in determining peritoneal sclerosis is supported by morphological studies and therefore backed by much biochemical and immunological data. (Int J Artif Organs 2005; 28: 85-9) 
INTRODUCTION
Simple peritoneal sclerosis is a frequent event in peritoneal dialysis, and can be observed in blood vessels from the first months of dialysis in most patients (1) (2) (3) (4) . Today most authors agree that dialysis solutions are the main cause of this phenomenon (5) (6) (7) .
In 1989, our group published a paper (8) confirming the previous findings of Gotloib (9) that after several months of peritoneal dialysis, it was possible to observe replication of the endothelial basement membrane of peritoneal arterial capillaries of non diabetic dialysis patients, identical to that observed in all vascular districts of diabetic patients after years of disease. From the morphological point of view, we demonstrated that the alterations were progressive and led to thickening of the basement membrane, culminating in complete occlusion of the vessel lumen. The similarities were so striking that we proposed peritoneal dialysis as an in vivo model in humans for studying the etiopathogenesis of diabetic microangiopathy (8) . However, this phenomenon is not only obser ved in the vascular endothelium of peritoneal dialysis patients: during dialysis the mesothelial basement membrane also replicates and thickens until it involves a considerable layer of submesothelial tissue. Gotloib and our group had no hesitation in sustaining that glucose and its breakdown products were the cause of the changes in peritoneal morphology observed in peritoneal dialysis patients.
Indeed, glucose concentrations in contact with the peritoneum are 10-30 times greater than in blood (10, 11) . Fifteen years of observations now enable us to delineate the evolution of alterations of the peritoneal mesothelial basement membrane in dialysis patients (3, 12, 13) .
Micrographs of peritoneal biopsy specimens of uremic patients before starting peritoneal dialysis show that the basement membrane carrying mesothelial cells is thin, single and adheres perfectly to the cytoplasmic digitations that introflect into the submesothelial connective tissue ( Fig. 1 ), as in normal subjects.
If we examine similar specimens of peritoneum after several months of peritoneal dialysis, doubling of the basement membrane can be observed in most cases, and the membrane no longer adheres to the cell, but detaches, creating interdigitations ( Figs. 2, 3 ). The picture is identical to that of the basal membrane of peritoneal vessels after several months of dialysis (3).
In peritoneal biopsies of patients with a longer history of peritoneal dialysis, besides intense replication of the basement membrane, we also observe confluence of the new membranes into a unit that in some cases resembles thickening. Also with regard to thickening, the evolution observed in the mesothelial basement membrane is the same as that observed in peritoneal vessels of the same patient and in general in the arteries of diabetics (Figs. 4, 5, 6). These stages of evolution observed by TEM are unfortunately not serial biopsies from the same patient, due to a question of costs. However, we doubt that this is a limitation, because we have observed hundreds of biopsies (3).
Finally, TEM and LM provide images that suggest that replication and thickening of the mesothelial basement membrane triggers a process of sclerosis ( Fig. 7) , first visible only by electron microscope, but later even by light microscope (Fig. 8 ). Indeed, once the microscopic picture becomes one of submesothelial sclerosis, we have never 86 observed any mesothelial basement membrane at all, either normal, replicated or thickened.
Morphology of peritoneal sclerosis
Similarities between endothelial and peritoneal mesothelial basement membrane lesions in peritoneal dialysis patients and vascular lesions in diabetics suggest that the glucose in peritoneal dialysis solutions plays a determinant role in the development of peritoneal sclerosis. It is easy to imagine that if blood sugar two or three times normal leads to endothelial basement membrane damage over a few years, peritoneal dialysis solutions with concentrations 15-30 times higher than in normal blood may damage the mesothelial basement membrane in a much briefer time. Morphological damage also varies from patient to patient. There may be submesothelial sclerosis after a few months of peritoneal dialysis or none after 1-2 years.
Our intuition about glucose, reported many years ago, has been sustained by many studies. In the last two years, there have been major contributions. Naiki et al (14) showed that high concentrations of glucose in peritoneal dialysis solutions stimulate high production of transforming growth factor-beta (TGF-ß), a mediator of fibrosis, accelerating peritoneal fibrosis, whereas Ogata (15) observed that low concentrations of glucose, lactate and glycated albumin and high concentrations of bicarbonate may preserve the viability of peritoneal mesothelial cells and prevent TGF-ß secretion which induces peritoneal fibrosis and neovascularization. De Vries et al (16) blocked glycation end products which prevented upregulation of TGF-ß, development of fibrosis and accumulation of fibronectin in the peritoneum of diabetic animals. Immunohistochemical studies of peritoneal-biopsy specimens from peritoneal dialysis patients by Yanez et al (17) demonstrated expression of two mesothelial markers, intercellular adhesion molecule 1 and cytokeratins, in fibroblast-like cells trapped in the stroma, suggesting that these cells stemmed from local conversion of mesothelial cells, probably promoting peritoneal fibrosis. Ha et al (18) found that vascular endothelial growth factor, transforming growth factor-beta1, procollagen I C-terminal peptide, procollagen III N-terminal peptide and fibronectin secreted by cultured human peritoneal mesothelial cells also induce peritoneal fibrosis. Animal models of Gillerot and Devuyst (19) have shown that local release of growth factors and nitric oxide in the peritoneal membrane may lead to areas of neovascularization and/or submesothelial fibrosis. Mortier et al (20) dialysed rats for 3 months with various peritoneal dialysis solutions, obser ving development of submesothelial fibrosis in those treated with solutions containing glucose and greater integrity of the peritoneal membrane in those treated with solutions containing amino acids. According to Musi (21) , long-term exposure to different components of glucose peritoneal dialysis solutions leads to mesothelial cell damage, submesothelial fibrosis, and neoangiogenesis. The results of studies by Tamuraet al (22) demonstrate that high glucose concentrations as well as high osmolarity inhibit FAKmediated migration of mesothelial cells, and suggest that dialysates containing high glucose concentrations may cause peritoneal damage by inhibiting wound healing in the mesothelial cell monolayer. Assuming that peritoneal macrophages take part in the process of peritoneal fibrosis and that monocyte chemoattractant protein-1 plays a role in recruiting monocytes toward the peritoneal cavity, Lee et al (23) demonstrated that high glucose of peritoneal dialysis solutions induced mesothelial MCP-1 expression partly via the tyrosine kinase-AP-1 pathway. Plum et al (24) showed clinically that patients characterized as high transporters by the peritoneal equilibration test had a thicker than normal submesothelial fibrous layer. Finally, Devuyst et al (25) , studying data from the Peritoneal Biopsy Registry, proposed that conventional acidic, lactate-buffered, glucosecontaining dialysis solutions contribute to both structural and functional changes in the dialysed peritoneal membrane, and in particular to fibrosis. The introduction of new, more biocompatible solutions could make it possible to reverse or attenuate these negative effects.
The role of glucose in determining peritoneal sclerosis is therefore backed by much biochemical and immunological data. The low biocompatibility of glucose towards the peritoneum in general has indeed been known for some time (8) (9) (10) (11) (12) (13) , as has the fact that its presence in peritoneal dialysis solutions favors the growth of any bacteria that find their way into the peritoneal cavity. peritoneal dialysis solutions are therefore worthwhile. Unfor tunately, a substance with the same osmotic potential as glucose, biocompatible with the peritoneum and without systemic effects, has not yet been found.
